Gina Mauro


Olaparib addition to abiraterone delays progression in frontline mCRPC

February 18, 2022

The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to abiraterone acetate in the frontline setting significantly improved radiographic progression-free survival versus placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer.